This article has been updated to include a statement from the Broad Institute.

NEW YORK (GenomeWeb) – CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics said Tuesday that the co-owners of intellectual property relating to CRISPR-Cas9 gene editing technology and licensed by these firms are seeking reversal of a decision by the US Patent and Trademark Office's Patent Trial and Appeal Board in a patent interference proceeding. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.